Compare DOMO & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMO | XGN |
|---|---|---|
| Founded | 2010 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.7M | 110.7M |
| IPO Year | 2018 | 2014 |
| Metric | DOMO | XGN |
|---|---|---|
| Price | $3.84 | $7.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $10.28 | $8.86 |
| AVG Volume (30 Days) | ★ 1.2M | 244.4K |
| Earning Date | 05-20-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $318,857,000.00 | N/A |
| Revenue This Year | $3.41 | $8.12 |
| Revenue Next Year | $4.72 | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.84 | $2.59 |
| 52 Week High | $18.49 | $12.23 |
| Indicator | DOMO | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 57.42 | 60.19 |
| Support Level | $3.32 | $4.08 |
| Resistance Level | $4.05 | $7.99 |
| Average True Range (ATR) | 0.15 | 0.40 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 75.31 | 58.29 |
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.